Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedMar 27, 2026
DataAggregated Company Financials
Companies20
  • 7D0.7%
  • 3M-25.9%
  • 1Y-44.1%
  • YTD-25.2%

In the last week, the Healthcare industry is flat overall, with ChemoMetec standing out by going down 25%. Unfortunately though, the industry is down 44% over the past 12 months. As for the next few years, earnings are expected to grow by 5.2% per annum.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 27 Mar 2026DKK 1.5tDKK 447.8bDKK 130.1b16.9x11.2x3.3x
Sun, 22 Feb 2026DKK 1.8tDKK 447.8bDKK 131.0b18.7x13.6x4x
Tue, 20 Jan 2026DKK 2.2tDKK 454.0bDKK 137.0b17.8x15.8x4.8x
Thu, 18 Dec 2025DKK 1.9tDKK 453.7bDKK 136.9b16.8x13.6x4.1x
Sat, 15 Nov 2025DKK 1.9tDKK 453.6bDKK 136.0b17.4x13.9x4.2x
Mon, 13 Oct 2025DKK 2.2tDKK 447.6bDKK 141.8b18.2x15.4x4.9x
Wed, 10 Sep 2025DKK 2.0tDKK 447.4bDKK 141.7b19.8x14.1x4.5x
Fri, 08 Aug 2025DKK 1.8tDKK 432.1bDKK 131.0b29.2x13.9x4.2x
Sun, 06 Jul 2025DKK 2.5tDKK 422.9bDKK 124.4b30.8x19.7x5.8x
Tue, 03 Jun 2025DKK 2.6tDKK 423.7bDKK 124.6b31.6x20.6x6.1x
Thu, 01 May 2025DKK 2.4tDKK 409.3bDKK 121.3b23x19.8x5.9x
Sat, 29 Mar 2025DKK 2.6tDKK 409.5bDKK 121.3b22.8x21.3x6.3x
Mon, 24 Feb 2025DKK 3.3tDKK 410.0bDKK 121.4b28.1x27.6x8.2x
Wed, 22 Jan 2025DKK 3.1tDKK 387.4bDKK 111.3b28.6x27.9x8x
Fri, 20 Dec 2024DKK 3.8tDKK 387.4bDKK 111.3b30.4x34.3x9.9x
Sun, 17 Nov 2024DKK 3.7tDKK 387.3bDKK 111.3b31.6x33.3x9.6x
Tue, 15 Oct 2024DKK 4.2tDKK 372.0bDKK 107.1b37x39.3x11.3x
Thu, 12 Sep 2024DKK 4.6tDKK 372.0bDKK 107.2b34.9x42.6x12.3x
Sat, 10 Aug 2024DKK 4.7tDKK 369.1bDKK 106.9b35.9x43.7x12.6x
Mon, 08 Jul 2024DKK 4.9tDKK 355.3bDKK 106.2b35.3x46.2x13.8x
Wed, 05 Jun 2024DKK 4.7tDKK 355.3bDKK 106.2b36.4x44.4x13.3x
Fri, 03 May 2024DKK 4.4tDKK 353.4bDKK 105.2b33.3x42.1x12.5x
Sun, 31 Mar 2024DKK 4.5tDKK 341.2bDKK 99.6b39.2x45.4x13.3x
Tue, 27 Feb 2024DKK 4.4tDKK 340.0bDKK 98.9b37.9x44.1x12.8x
Thu, 25 Jan 2024DKK 3.7tDKK 320.5bDKK 90.0b35.6x41.6x11.7x
Sat, 23 Dec 2023DKK 3.6tDKK 320.4bDKK 90.0b32.7x40.2x11.3x
Mon, 20 Nov 2023DKK 3.6tDKK 320.5bDKK 90.0b33.7x40x11.2x
Wed, 18 Oct 2023DKK 3.7tDKK 305.5bDKK 82.2b29.9x44.5x12x
Fri, 15 Sep 2023DKK 3.6tDKK 305.5bDKK 82.2b35.9x43.8x11.8x
Sun, 13 Aug 2023DKK 3.3tDKK 301.3bDKK 81.0b41.3x40.8x11x
Tue, 11 Jul 2023DKK 2.9tDKK 287.0bDKK 75.5b38.9x38.5x10.1x
Thu, 08 Jun 2023DKK 3.0tDKK 287.2bDKK 75.5b40.1x39.8x10.5x
Sat, 06 May 2023DKK 3.0tDKK 284.0bDKK 74.5b39.3x40.8x10.7x
Mon, 03 Apr 2023DKK 3.0tDKK 291.1bDKK 69.0b38.5x43.6x10.3x
Price to Earnings Ratio

43.6x


Total Market Cap: DKK 3.0tTotal Earnings: DKK 69.0bTotal Revenue: DKK 291.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 32x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 11.2x which is lower than its 3-year average PE of 32.0x.
  • The 3-year average PS ratio of 9.1x is higher than the industry's current PS ratio of 3.3x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 24% per year over the last three years.
  • Revenues for these companies have grown 15% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market0.35%
Healthcare0.68%
Biotech3.10%
Medical Equipment2.16%
Pharma0.33%
Healthcare Services-1.22%
Healthtech-1.51%
Life Sciences-13.39%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 489x.
    • Analysts are expecting annual earnings growth of 85.3%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 85% over the next 5 years.
  • This is better than its past earnings decline of 100% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 9.5% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GMAB GenmabDKK 1.69k2.9%
+DKK 3.0b		21.1%PE16.6x
NOVO B Novo NordiskDKK 238.450.2%
+DKK 2.1b		-50.4%PE10.3x
COLO B ColoplastDKK 435.601.9%
+DKK 1.8b		-40.5%PE24.6x
DEMANT DemantDKK 189.204.6%
+DKK 1.8b		-23.1%PE16.9x
HLUN B H. LundbeckDKK 38.724.3%
+DKK 1.6b		6.6%PE12x

Latest News

NOVO B
DKK 238.45
Novo Nordisk
7D
0.2%
1Y
-50.4%
ZEAL
DKK 287.90
Zealand Pharma
7D
2.9%
1Y
-46.0%
BIOPOR
DKK 0.88
BioPorto
7D
-5.6%
1Y
-37.0%
CHEMM
DKK 297.00
ChemoMetec
7D
-24.7%
1Y
-41.0%
ALK B
DKK 203.80
ALK-Abelló
7D
-0.4%
1Y
45.9%

ALK B: Future Upside Will Rely On Wider Anaphylaxis Spray Adoption

Analysts have kept their DKK price target for ALK-Abelló broadly unchanged at DKK 255, reflecting stable assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. This signals a steady view on the company’s outlook.
DEMANT
DKK 189.20
Demant
7D
4.6%
1Y
-23.1%

DEMANT: Recent Upgrades And 2026 Guidance May Support Further Upside

Analysts have trimmed the fair value estimate for Demant slightly to DKK 231.61 from DKK 232.17, reflecting a modest recalibration of price targets after a mix of recent upgrades and target reductions across the Street. Analyst Commentary Recent research on Demant has been mixed, with both upgrades and target cuts contributing to the slightly lower blended fair value estimate.
EMBLA
DKK 26.00
Embla Medical hf
7D
-3.3%
1Y
-4.8%

EMBLA: Capital Reduction And Buybacks Will Support Attractive Long Term Upside

Analysts have kept the fair value estimate for Embla Medical hf. steady at DKK 34.00.
BAVA
DKK 192.00
Bavarian Nordic
7D
4.7%
1Y
21.8%
AMBU B
DKK 69.25
Ambu
7D
1.9%
1Y
-42.4%

AMBU B: Lower P/E Assumptions Will Support Upside If Execution Improves

Analysts have lowered their price target on Ambu by DKK 12 to reflect slightly adjusted assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E following the recent JPMorgan target cut to DKK 12. Analyst Commentary Bullish Takeaways Bullish analysts see the revised fair value and discount rate assumptions as a reset that could leave room for upside if Ambu delivers on its operational targets.
HLUN B
DKK 38.72
H. Lundbeck
7D
4.3%
1Y
6.6%

HLUN B: Neurology Pipeline Progress Will Support Future Margin Expansion

Analysts have reduced their price target on H. Lundbeck to DKK 61.99 from DKK 66.52, reflecting updated assumptions for slightly softer revenue growth, profit margins, and a lower future P/E multiple.
NNIT
DKK 43.95
NNIT
7D
-1.7%
1Y
-38.2%
GMAB
DKK 1,693.50
Genmab
7D
2.9%
1Y
21.1%

GMAB: 2026 Catalyst Calendar Will Likely Expose Downside Risk Ahead

Analysts have lifted the Genmab fair value estimate from DKK 1,075.93 to DKK 1,300.00, reflecting updated views on revenue growth, profitability and future P/E, following recent price target revisions and renewed coverage across the Street. Analyst Commentary Recent Street research on Genmab points to a mix of optimism and caution, with valuation views reset around updated expectations for key pipeline assets and royalty streams.
GUBRA
DKK 364.80
Gubra
7D
-0.5%
1Y
-17.5%

GUBRA: Future Obesity Trial And Ventures Platform Will Drive Upside Potential

Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing model adjustments that reflect a slightly higher discount rate, softer revenue expectations, a lower projected profit margin and a higher future P/E multiple. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study aimed at high quality weight loss, with a design that looks at safety, tolerability, pharmacokinetics, preliminary efficacy, muscle volume and muscle function in about 188 participants, including both healthy volunteers and people living with obesity, as a standalone therapy and in combination with incretin based treatment.
COLO B
DKK 435.60
Coloplast
7D
1.9%
1Y
-40.5%
SMSMED
DKK 3.23
Scandinavian Medical Solutions
7D
-1.2%
1Y
-25.6%

Sentiment Still Eluding Scandinavian Medical Solutions A/S (CPH:SMSMED)

Jan 27
Sentiment Still Eluding Scandinavian Medical Solutions A/S (CPH:SMSMED)
STRAP
DKK 564.00
Strategic Partners
7D
-9.0%
1Y
-29.5%